Glucosamine powder for solution for oral administration 1500mg in bags No. 10

Name:
Glucosamine. Release form Powder for solution for oral administration. Dosage 1.5 g 3.5 g. Pack quantity: 10 pcs. ProducerAmantismed Ltd. INN Glucosamine. FTGNpvp.
Description:
Powder consisting of particles of varying degrees of grinding, from white to white with a yellowish or white with a grayish tint. Composition Each package contains: active substance: glucosamine hydrochloride – 1500 mg; excipients: macrogol 4000, anhydrous citric acid, sorbitol. Pharmacotherapeutic group Other nonsteroidal anti-inflammatory and antirheumatic drugs. ATX code: M01AX05 Pharmacological action Glucosamine hydrochloride is a salt of the amino monosaccharide glucosamine, which is an endogenous component and a preferred substrate for the synthesis of glycosaminoglycans and proteoglycans of articular cartilage and synovial fluid. Glucosamine inhibits the activity of interleukin-1-β and other inflammatory mediators. Clinical efficacy and tolerability. The safety and efficacy of glucosamine has been confirmed in clinical trials with treatment durations up to three years. Short- and medium-term clinical studies have shown that the effectiveness of glucosamine in relation to the symptoms of osteoarthritis is observed after 2-3 weeks of its use. However, unlike NSAIDs, glucosamine has a long-lasting effect that lasts from 6 months to 3 years. Clinical studies with daily glucosamine for up to 3 years have shown a gradual improvement in disease symptoms and a slowdown in structural changes in the joint, as demonstrated by plain radiography. Glucosamine has been shown to be well tolerated in both short and long term treatments. Evidence of the effectiveness of the drug was demonstrated when it was taken for three months, with a residual effect for two months after its withdrawal. The safety and efficacy of the drug have also been confirmed in clinical trials for up to three years of use. Continuous treatment for more than 3 years is not recommended, as there are no safety data when taking glucosamine for more than 3 years. Indications for use Relief of symptoms (mild to moderate pain) in adequately diagnosed osteoarthritis of the knee. Method of application and dosage Inside, one packet (1500 mg) 1 time per day, preferably with meals. The contents of one package should be dissolved in a glass of boiled and cooled to room temperature water. Glucosamine is not intended for the treatment of acute pain symptoms. Relief of symptoms (especially pain relief) may occur only after several weeks of use, and sometimes longer. If symptoms are not relieved after 2-3 months of glucosamine, treatment should be reassessed. Patients should seek medical advice if pain worsens after starting glucosamine. Dosage regimen in different categories of patients Elderly patients Dose adjustment in elderly patients is not required. Patients with impaired renal and/or hepatic function No studies have been conducted on the use of glucosamine in patients with impaired renal and/or hepatic function, therefore, there are no dosage recommendations for such patients. Children and adolescents Glucosamine should not be used in children and adolescents under the age of 18 years, as there are no data on the safety and efficacy of glucosamine in this category of patients. Side effect The frequency of development of adverse events is given in the following gradation: very often (≥ 1/10); often (≥ 1/100, < 1/10); infrequently (≥ 1/1000, < 1/100); rarely (≥ 1/10000, < 1/1000); very rarely (< 1/10000); unknown (according to the available data, it is not possible to determine the frequency of occurrence). The most common adverse events associated with oral glucosamine are nausea, abdominal pain, dyspepsia, flatulence, constipation, and diarrhea. These adverse reactions were generally mild and transient. From the immune system: unknown: allergic reactions *; From the side of metabolism and nutrition: unknown: inadequate glycemic control in diabetes; Mental disorders: unknown: insomnia; From the nervous system: often: headache, drowsiness; unknown: dizziness; On the part of the organ of vision: unknown: visual impairment; From the side of the heart: unknown: arrhythmias, including tachycardia; From the side of the vessels: infrequently: hot flashes; On the part of the respiratory system, chest organs and mediastinum: unknown: asthma / worsening of asthma; Gastrointestinal disorders: often: diarrhea, constipation, nausea, flatulence, abdominal pain, dyspepsia; unknown: vomiting; From the skin and subcutaneous tissues: infrequently: erythema, itching, rash; unknown: angioedema, urticaria; From the side of the liver and biliary tract: unknown: jaundice, increased levels of "liver" enzymes in the blood **; General disorders: often: fatigue; unknown: edema/peripheral edema; Laboratory and instrumental data: unknown: increased "liver" enzymes, blood glucose levels, increased blood pressure, fluctuations in the INR. *Predisposed patients may develop serious allergic reactions to glucosamine. ** Cases of jaundice and elevated liver enzymes have been reported, but a causal relationship with glucosamine use has not been established. Cases of hypercholesterolemia have been reported, but a causal relationship with glucosamine use has not been demonstrated. Contraindications Hypersensitivity to glucosamine or any of the excipients. Powder for oral solution contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine. The drug should not be taken by patients who are allergic to shellfish, because. the active substance (glucosamine) is obtained from mollusks and crustaceans. Pregnancy and the period of breastfeeding. Overdose No cases of accidental or intentional overdose are known. In case of an overdose, glucosamine should be discontinued, symptomatic treatment aimed at restoring the water and electrolyte balance. Precautions Before using glucosamine, you should consult your doctor to exclude the presence of joint diseases for which other methods of treatment are provided. Cases of exacerbation of symptoms of bronchial asthma after the start of taking glucosamine are described. Patients suffering from bronchial asthma should be informed about the possible worsening of the symptoms of the disease. Patients with impaired glucose tolerance should be careful when taking glucosamine. Patients with diabetes mellitus are advised to monitor glycemic levels and determine the need for insulin before starting and periodically during treatment. The sorbitol contained in the medicinal product can cause osmotic diarrhea. Special studies in patients with impaired renal and / or liver function have not been conducted. Based on the toxicological and pharmacokinetic studies of glucosamine, dose restrictions should not be considered in such patients. However, the use of glucosamine in patients with severe hepatic or renal insufficiency should be carried out under the supervision of a physician. Use during pregnancy and lactation No studies have been conducted on the efficacy and safety of glucosamine in pregnant and lactating women, and therefore, the drug is not recommended for women during pregnancy and lactation. Influence on the ability to drive vehicles and other potentially dangerous mechanisms No studies have been conducted on the effect of glucosamine on the ability to drive vehicles and other potentially dangerous mechanisms. You should refrain from driving vehicles and other mechanisms in case of drowsiness, dizziness, fatigue, headache or visual impairment. Interaction with other medicinal productsSpecial studies on the interaction of glucosamine with other medicinal products have not been conducted. There are reports of an increased effect of coumarin anticoagulants, so in patients who are simultaneously taking coumarin anticoagulants (for example, warfarin or acenocoumarol), more careful monitoring of coagulation parameters is necessary. Oral administration of glucosamine may increase the absorption of tetracyclines from the gastrointestinal tract, but the clinical significance of this interaction is low. The drug is compatible with non-steroidal anti-inflammatory drugs and glucocorticosteroids. Storage conditions In a place protected from moisture and light at a temperature not exceeding 25 ° C. Keep out of the reach of children. Shelf life 2 years. Do not use after the expiry date stated on the package. Packing: 3500 mg (1500 mg of active substance) in bags of multilayer packaging material (polyethylene terephthalate film / polypropylene film / aluminum foil / polyethylene film). 10 or 20 packs together with instructions for medical use in a cardboard pack. Conditions for dispensing from pharmacies Without a doctor's prescription. ProducerAmantisMed LLC Buy Glucosamine powder for oral solution 1500 mg in bags No. 10 Price for Glucosamine powder for oral solution 1500 mg in bags No. 10 Instructions for use for Glucosamine powder for oral solution inside 1500mg in packages No. 10